Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B

Phase 2Recruiting

1 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gestational Trophoblastic Neoplasia

Conditions

Gestational Trophoblastic Neoplasia

Trial Timeline

Jan 27, 2022 → Jan 1, 2027

NCT ID

NCT05139095

About Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B

Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Gestational Trophoblastic Neoplasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05139095. Target conditions include Gestational Trophoblastic Neoplasia.

What happened to similar drugs?

5 of 10 similar drugs in Gestational Trophoblastic Neoplasia were approved

Approved (5) Terminated (1) Active (4)

✅Insulin LISPRO + Insulin, Long-Acting and InsulinEli LillyApproved

✅Metformin + placeboNovo NordiskApproved

✅Liraglutide + PlaceboNovo NordiskApproved

✅Genotropin (somatropin)PfizerApproved

✅OmnitropeSandoz GroupApproved

🔄somatropinEli LillyPhase 3

❌Recombinant human growth hormone (r-hGH)MerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05139095	Phase 2	Recruiting	Jan 27, 2022	Jan 1, 2027	Gestational Trophoblastic Neoplasia

Competing Products

18 competing products in Gestational Trophoblastic Neoplasia

See all competitors

Product	Company	Stage	Hype Score
somatropin	Eli Lilly	Phase 3	40
Insulin LISPRO + Insulin, Long-Acting and Insulin	Eli Lilly	Approved	43
Pembrolizumab Injection [Keytruda]	Merck	Phase 2	31
recombinant somatropin	Merck	Pre-clinical	26
Recombinant human growth hormone (r-hGH)	Merck	Phase 3	32
Avelumab Injection + Methotrexate 1 GM Injection	Merck	Phase 1/2	39
Saizen® + Saizen®	Merck	Phase 3	40
Metformin + placebo	Novo Nordisk	Approved	39
Metformin XR plus placebo + Metformin XR plus liraglutide	Novo Nordisk	Phase 3	40
Somapacitan + Norditropin®	Novo Nordisk	Phase 2	39
Liraglutide + Placebo	Novo Nordisk	Approved	43
Genotropin (PN-180,307) Somatropin + Control-no treatment	Pfizer	Phase 3	40
growth hormone	Pfizer	Pre-clinical	26
Somatropin	Pfizer	Pre-clinical	26
Somatropin	Pfizer	Pre-clinical	26
Genotropin (somatropin)	Pfizer	Approved	43
Omnitrope	Sandoz Group	Approved	40
Inhaled Technosphere Insulin	MannKind Corp	Phase 2/3	39